Aclaris Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Aclaris Therapeutics, Inc.‘s stocks are currently a part of 109 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 59.37M shares of Aclaris Therapeutics, Inc.. Compared to the previous quarter, the number grew by 5.95% or 3.33M shares more. As for the holding position changes, 33.94% (37) of current hedge fund investors increased the number of shares held, 38.53% (42) of current holders sold a part of the shares held, and 28.44% (31) closed the holdings completely. 10 hedge funds are new holders of Aclaris Therapeutics, Inc. stock in Q1 2022, it is 9.17% of total holders.
Hedge funds holding Aclaris Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 102 |
|---|---|
| Q3 2017 | 104 |
| Q4 2017 | 102 |
| Q1 2018 | 99 |
| Q2 2018 | 93 |
| Q3 2018 | 83 |
| Q4 2018 | 95 |
| Q1 2019 | 92 |
| Q2 2019 | 81 |
| Q3 2019 | 78 |
| Q4 2019 | 75 |
| Q1 2020 | 67 |
| Q2 2020 | 58 |
| Q3 2020 | 53 |
| Q4 2020 | 80 |
| Q1 2021 | 95 |
| Q2 2021 | 127 |
| Q3 2021 | 125 |
| Q4 2021 | 134 |
| Q1 2022 | 109 |
Hedge funds changes in Aclaris Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 16 | 56 | 22 | 25 | -17 |
|---|---|---|---|---|---|
| Q3 2017 | 13 | 54 | 24 | 11 | 2 |
| Q4 2017 | 19 | 39 | 34 | 21 | -11 |
| Q1 2018 | 14 | 46 | 28 | 16 | -5 |
| Q2 2018 | 12 | 40 | 27 | 17 | -3 |
| Q3 2018 | 5 | 33 | 28 | 16 | 1 |
| Q4 2018 | 24 | 41 | 21 | 12 | -3 |
| Q1 2019 | 15 | 36 | 24 | 18 | -1 |
| Q2 2019 | 13 | 33 | 27 | 22 | -14 |
| Q3 2019 | 14 | 20 | 29 | 17 | -2 |
| Q4 2019 | 10 | 25 | 24 | 13 | 3 |
| Q1 2020 | 12 | 17 | 22 | 16 | 0 |
| Q2 2020 | 10 | 14 | 20 | 20 | -6 |
| Q3 2020 | 6 | 12 | 20 | 11 | 4 |
| Q4 2020 | 32 | 15 | 22 | 4 | 7 |
| Q1 2021 | 33 | 32 | 25 | 17 | -12 |
| Q2 2021 | 50 | 33 | 32 | 18 | -6 |
| Q3 2021 | 21 | 51 | 36 | 22 | -5 |
| Q4 2021 | 29 | 49 | 37 | 18 | 1 |
| Q1 2022 | 10 | 37 | 42 | 31 | -11 |
Hedge funds changes in Aclaris Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 3,801,000 | 0 |
|---|---|---|
| Q3 2017 | 4,236,000 | 354,000 |
| Q4 2017 | 20,000 | 1,489,000 |
| Q1 2018 | 0 | 254,000 |
| Q2 2018 | 1,457,000 | 675,000 |
| Q3 2018 | 0 | 0 |
| Q4 2018 | 123,000 | 7,000 |
| Q1 2019 | 68,000 | 288,000 |
| Q2 2019 | 0 | 414,000 |
| Q3 2019 | 1,000 | 46,000 |
| Q4 2019 | 112,000 | 1,000 |
| Q1 2020 | 7,000 | 1,000 |
| Q2 2020 | 1,000 | 0 |
| Q3 2020 | 69,000 | 1,000 |
| Q4 2020 | 3,075,000 | 240,000 |
| Q1 2021 | 6,404,000 | 4,214,000 |
| Q2 2021 | 3,319,000 | 2,879,000 |
| Q3 2021 | 2,328,000 | 807,000 |
| Q4 2021 | 2,147,000 | 31,000 |
| Q1 2022 | 1,154,000 | 217,000 |